Celltrion's drive remains relentless despite being joined on 'lonely path' by host of biosimilar manufacturers

13 April 2018

It was no fluke when Celltrion Healthcare (Kosdaq: 068270) became the first drug developer to win approval for a biosimilar monoclonal antibody (MAb) from the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) with its copy of Remicade (infliximab).

The first approval for that product, Remsima, came in Celltrion’s native Korea in 2012, and while it marked the start of the opening up of the MAb biosimilar market that other players have since entered, before then this field was a “difficult and lonely” path, chief executive Woo Sung Kee has said.

There was huge capital and technical expertise needed to copy biologic drugs, unlike producing generic copies, and Celltrion was the first to walk this path.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK